drugset / Trial / NCT04784533

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533

Phase 2 Completed 317 enrolled Concert Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

Timeline

Start
2021-02-26
Primary completion
2023-05-16
Completion
2023-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 4 mg Oral
Subject CTP-543 Unknown 8 mg Oral
Subject CTP-543 Unknown 12 mg Oral

Indications